Summary:
AstraZeneca Pharma India has signed a Letter of Intent with Reliance Industries subsidiary Strand Life Sciences to explore potential collaboration in India’s healthcare sector. The proposed partnership aims to combine AstraZeneca’s pharmaceutical research capabilities with Strand’s expertise in genomics and diagnostics to advance healthcare innovation. Announced on November 17, 2026, the agreement is not classified as a related-party transaction. However, details regarding investments, joint projects and implementation timelines are yet to be disclosed.
AstraZeneca Pharma India has entered into a Letter of Intent (LOI) with Strand Life Sciences, a genomics research and diagnostic firm and a subsidiary of Reliance Industries Limited, to assess potential partnership opportunities in India’s healthcare industry.
Announced on November 17, 2026, the agreement provides a basis for the two organisations to identify and evaluate areas of shared interest in the healthcare sector. The proposed association combines AstraZeneca’s pharmaceutical and research strengths with Strand Life Sciences’ capabilities in genomics research and diagnostic services.
The company also clarified that signing the Letter of Intent does not fall under related-party transaction regulations. Both AstraZeneca Pharma India and Strand Life Sciences are classified as independent parties under the relevant corporate governance guidelines.
Speaking about the development, Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India, stated, “The continued growth demonstrates the strength of AstraZeneca’s science-led portfolio and our ability to translate innovation into meaningful impact for patients in India. We are accelerating our efforts across oncology, biopharmaceuticals and rare disease.”
The proposed partnership highlights the growing focus on advancing healthcare innovation and developing strategic alliances across India’s expanding life sciences sector. However, details concerning specific joint initiatives, financial investments, implementation schedules or commercial agreements have not yet been made public.







